FKBP12.6 protects heart from AngII-induced hypertrophy through inhibiting Ca2+ /calmodulin-mediated signalling pathways in vivo and in vitro

CD38 promotes angiotensin II-induced cardiac hypertrophy

(2017) Xiao-Hui Guan et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

mTOR, cardiomyocytes and inflammation in cardiac hypertrophy

(2016) Lifen Xu et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH

Molecular networks underlying myofibroblast fate and fibrosis

(2016) April Stempien-Otero et al.   JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY

Physiological and pathological cardiac hypertrophy

(2016) Ippei Shimizu et al.   JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY

Insights Into the Activation and Inhibition of Angiotensin II Type 1 Receptor in the Mechanically Loaded Heart

(2014) Jian Wu et al.   CIRCULATION JOURNAL

Angiotensin II type 1a receptor signalling directly contributes to the increased arrhythmogenicity in cardiac hypertrophy

(2013) Shinji Yasuno et al.   BRITISH JOURNAL OF PHARMACOLOGY

Ca2+ Fluxes Involvement in Gene Expression During Cardiac Hypertrophy

(2013) Ana Gomez et al.   Current Vascular Pharmacology

FK506 binding proteins: Cellular regulators of intracellular Ca2+ signalling

(2013) Debbi MacMillan   EUROPEAN JOURNAL OF PHARMACOLOGY

Cardiac FKBP12.6 overexpression protects against triggered ventricular tachycardia in pressure overloaded mouse hearts

(2012) Laurent Vinet et al.   BASIC RESEARCH IN CARDIOLOGY

Sasanquasaponin up-regulates anion exchanger 3 expression and elicits cardioprotection via NO/RAS/ERK1/2 pathway

(2012) He-Ping Chen et al.   CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY

Targeting the TGFβ signalling pathway in disease

(2012) Rosemary J. Akhurst et al.   NATURE REVIEWS DRUG DISCOVERY

Rapamycin treatment augments both protein ubiquitination and Akt activation in pressure-overloaded rat myocardium

(2011) Rebecca K. Harston et al.   AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY

Transgenic Analysis of the Role of FKBP12.6 in Cardiac Function and Intracellular Calcium Release

(2011) Ying Liu et al.   ASSAY AND DRUG DEVELOPMENT TECHNOLOGIES

Cell Signaling of Angiotensin II on Vascular Tone: Novel Mechanisms

(2011) Aurelie Nguyen Dinh Cat et al.   CURRENT HYPERTENSION REPORTS

Angiotensin II and norepinephrine activate specific calcineurin-dependent NFAT transcription factor isoforms in cardiomyocytes

(2011) Ida G. Lunde et al.   JOURNAL OF APPLIED PHYSIOLOGY

Ca2+ signalling in cardiovascular disease: the role of the plasma membrane calcium pumps

(2011) Elizabeth J. Cartwright et al.   Science China-Life Sciences

Cardiac angiotensin II: does it have a function?

(2010) A. H. Jan Danser   AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY

The H9C2 cell line and primary neonatal cardiomyocyte cells show similar hypertrophic responses in vitro

(2010) Sarah J. Watkins et al.   IN VITRO CELLULAR & DEVELOPMENTAL BIOLOGY-ANIMAL

Molecular distinction between physiological and pathological cardiac hypertrophy: Experimental findings and therapeutic strategies

(2010) Bianca C. Bernardo et al.   PHARMACOLOGY & THERAPEUTICS

Dissociation of FKBP12.6 from ryanodine receptor type 2 is regulated by cyclic ADP-ribose but not β-adrenergic stimulation in mouse cardiomyocytes

(2009) Xu Zhang et al.   CARDIOVASCULAR RESEARCH

Angiotensin II–Mediated Adaptive and Maladaptive Remodeling of Cardiomyocyte Excitation–Contraction Coupling

(2009) Konstantin Gusev et al.   CIRCULATION RESEARCH

A novel signaling pathway of ADP-ribosyl cyclase activation by angiotensin II in adult rat cardiomyocytes

(2008) Rukhsana Gul et al.   AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY

Conditional FKBP12.6 Overexpression in Mouse Cardiac Myocytes Prevents Triggered Ventricular Tachycardia Through Specific Alterations in Excitation- Contraction Coupling

(2008) Barnabas Gellen et al.   CIRCULATION

ADENOVIRUS-MEDIATED FKBP12.6 OVEREXPRESSION INDUCES HYPERTROPHY AND APOPTOSIS IN CULTURED NEONATAL CARDIOMYOCYTES

(2008) Jian Zhong et al.   CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY

Angiotensin II: A hormone involved in and contributing to pro-hypertrophic cardiac networks and target of anti-hypertrophic cross-talks

(2008) K.-D. Schlüter et al.   PHARMACOLOGY & THERAPEUTICS